BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 6610851)

  • 1. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
    Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
    Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
    Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children.
    Rosen G; Ghavimi F; Nirenberg A; Mosende C; Mehta BM
    Cancer Treat Rep; 1977 Jul; 61(4):681-90. PubMed ID: 301781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antineoplastic agents: high-dose methotrexate and citrovorum factor rescue.
    Sadée W
    Ther Drug Monit; 1980; 2(2):177-85. PubMed ID: 6762711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)].
    Leber H; Kotz R; Chiari K; Endler T; Gabl F; Krisch K; Salzer-Kuntschik M
    Wien Klin Wochenschr; 1981 Apr; 93(7):236-40. PubMed ID: 7020262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
    Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
    Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue.
    Isacoff WH; Morrison PF; Aroesty J; Willis KL; Block JB; Lincoln TL
    Cancer Treat Rep; 1977 Dec; 61(9):1665-74. PubMed ID: 304376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
    Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue.
    Isacoff WH; Eilber F; Tabbarah H; Klein P; Dollinger M; Lemkin S; Sheehy P; Cone L; Rosenbloom B; Sieger L; Block JB
    Cancer Treat Rep; 1978 Sep; 62(9):1295-304. PubMed ID: 356984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
    Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of administration of massive doses of methotrexate (50 g) with equimolar citrovorum factor rescue in adult patients.
    Reggev A; Djerassi I
    Cancer; 1988 Jun; 61(12):2423-8. PubMed ID: 3259154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma.
    Wang YM; Sutow WW; Romsdahl MM; Perez C
    Cancer Treat Rep; 1979 Mar; 63(3):405-10. PubMed ID: 284845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of severe side effects of high-dose methotrexate in osteosarcoma].
    Umeda T; Takada N; Hodaka E; Endoh F; Ishii T
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):285-94. PubMed ID: 6582805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor).
    Juergens H; Kosloff C; Nirenberg A; Mehta BM; Huvos AG; Rosen G
    Natl Cancer Inst Monogr; 1981 Apr; (56):221-6. PubMed ID: 6975439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
    Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
    Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
    Pitman SW; Frei E
    Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of solid tumors using high-dose methotrexate and citrovorum factor].
    Baumgartner G; Heinz R; Karrer K; Pridun N; Lutz D
    Osterr Z Onkol; 1977; 3(5-6):141-8. PubMed ID: 300863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Severe renal impairment of methotrexate elimination after high dose therapy].
    Lawrenz-Wolf B; Wolfrom C; Frickel C; Fengler R; Wehinger H; Henze G
    Klin Padiatr; 1994; 206(4):319-26. PubMed ID: 7967432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.